In addition, adoptive transferal of TRAIL-treated T cells developed a later onset and less severe colitis (Supplementary Fig. S5), suggesting TRAIL suppresses colitogenic T-cell activation and further inhibits the development of colitis. Here, TNFSF10 is linked to colitis.